In the last trading session, 1.08 million shares of the Mineralys Therapeutics Inc (NASDAQ:MLYS) were traded, and its beta was -0.41. Most recently the company’s share price was $16.17, and it changed around -$0.7 or -4.15% from the last close, which brings the market valuation of the company to $1.02B. MLYS currently trades at a discount to its 52-week high of $18.38, offering almost -13.67% off that amount. The share price’s 52-week low was $8.24, which indicates that the current value has risen by an impressive 49.04% since then. We note from Mineralys Therapeutics Inc’s average daily trading volume that its 10-day average is 1.84 million shares, with the 3-month average coming to 797.41K.
Mineralys Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended MLYS as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Instantly MLYS has showed a red trend with a performance of -4.15% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 18.38 on recent trading dayincreased the stock’s daily price by 12.02%. The company’s shares are currently up 31.36% year-to-date, but still up 13.71% over the last five days. On the other hand, Mineralys Therapeutics Inc (NASDAQ:MLYS) is 69.14% up in the 30-day period. We can see from the shorts that 2.01 million shares have been sold at a short interest cover period of 5.94 day(s).
The consensus price target as assigned by Wall Street analysts is $30, which translates to bulls needing to increase their stock price by 46.1% from its current value. Analyst projections state that MLYS is forecast to be at a low of $30 and a high of $30.
Mineralys Therapeutics Inc (MLYS) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -170.42%. Mineralys Therapeutics Inc earnings are expected to increase by -6.33% in 2025, but the outlook is negative -3.06% per year for the next five years.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.00% of Mineralys Therapeutics Inc shares, and 87.07% of them are in the hands of institutional investors. The stock currently has a share float of 88.85%. Mineralys Therapeutics Inc stock is held by 157.0 institutions, with CATALYS PACIFIC, LLC being the largest institutional investor. By 2024-06-30, it held 18.629% of the shares, which is about 9.19 million shares worth $107.58 million.
SAMSARA BIOCAPITAL, LLC, with 10.2822% or 5.07 million shares worth $59.38 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
